Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenzo Toschi

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Current Opinion in Molecular Therapeutics|October 2, 2010
OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIIIVincenzo Toschi
Internal and Emergency Medicine|September 21, 2010
Blood-born tissue factor in cardiovascular disease: where are we now?Vincenzo Toschi
Giornale Italiano Di Cardiologia (2006)|May 26, 2021
[Thrombosis and COVID-19 vaccine: much ado about nothing?]Vincenzo Toschi
Giornale Italiano Di Cardiologia (2006)|May 25, 2023
[Ten questions related to heparin-induced thrombocytopenia]Vincenzo Toschi
British Journal of Clinical Pharmacology|May 7, 2011
Inhibitors of propagation of coagulation: factors V and XVincenzo Toschi, Maddalena Lettino
Giornale Italiano Di Cardiologia (2006)|May 20, 2011
[Impact of anemia and its treatment in patients with acute coronary syndromes]Maddalena Lettino, Vincenzo Toschi
Evidence-Based Cardiovascular Medicine|December 29, 2005
Early invasive strategy has higher short term mortality but better longer term efficacy compared to selective strategy for people with NSTEMI. Commentary 1Maddalena Lettino, Vincenzo Toschi
Internal and Emergency Medicine|April 22, 2010
Diagnosis, laboratory aspects and management of acquired hemophilia AVincenzo Toschi, Francesco Baudo
Giornale Italiano Di Cardiologia (2006)|September 29, 2024
[Hematologic malignancies and increased cardiovascular risk: a new issue to be considered for patient follow-up]Vincenzo Toschi, Maddalena Lettino
Blood|December 4, 2010
Tissue factor expression on platelets is a dynamic eventMarina Camera, Marta Brambilla, Vincenzo Toschi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Current Opinion in Molecular Therapeutics|October 2, 2010
OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIIIVincenzo Toschi
Internal and Emergency Medicine|September 21, 2010
Blood-born tissue factor in cardiovascular disease: where are we now?Vincenzo Toschi
Giornale Italiano Di Cardiologia (2006)|May 26, 2021
[Thrombosis and COVID-19 vaccine: much ado about nothing?]Vincenzo Toschi
Giornale Italiano Di Cardiologia (2006)|May 25, 2023
[Ten questions related to heparin-induced thrombocytopenia]Vincenzo Toschi
British Journal of Clinical Pharmacology|May 7, 2011
Inhibitors of propagation of coagulation: factors V and XVincenzo Toschi, Maddalena Lettino
Giornale Italiano Di Cardiologia (2006)|May 20, 2011
[Impact of anemia and its treatment in patients with acute coronary syndromes]Maddalena Lettino, Vincenzo Toschi
Evidence-Based Cardiovascular Medicine|December 29, 2005
Early invasive strategy has higher short term mortality but better longer term efficacy compared to selective strategy for people with NSTEMI. Commentary 1Maddalena Lettino, Vincenzo Toschi
Internal and Emergency Medicine|April 22, 2010
Diagnosis, laboratory aspects and management of acquired hemophilia AVincenzo Toschi, Francesco Baudo
Giornale Italiano Di Cardiologia (2006)|September 29, 2024
[Hematologic malignancies and increased cardiovascular risk: a new issue to be considered for patient follow-up]Vincenzo Toschi, Maddalena Lettino
Blood|December 4, 2010
Tissue factor expression on platelets is a dynamic eventMarina Camera, Marta Brambilla, Vincenzo Toschi, et al.
Pageof 3